Renaissance Technologies LLC Increases Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Renaissance Technologies LLC grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 253.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,145,056 shares of the company's stock after purchasing an additional 821,156 shares during the period. Renaissance Technologies LLC owned approximately 0.43% of Autolus Therapeutics worth $3,985,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $11,793,000. Price T Rowe Associates Inc. MD increased its holdings in Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company's stock worth $35,020,000 after acquiring an additional 2,487,778 shares during the period. BNP Paribas Financial Markets increased its holdings in Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company's stock worth $736,000 after acquiring an additional 111,131 shares during the period. Bank of New York Mellon Corp increased its holdings in Autolus Therapeutics by 74.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company's stock worth $8,810,000 after acquiring an additional 1,080,897 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after acquiring an additional 15,293 shares during the period. Institutional investors own 72.83% of the company's stock.

Analysts Set New Price Targets

AUTL has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. William Blair reaffirmed an "outperform" rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.70.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL traded up $0.15 during trading on Friday, reaching $3.63. The company had a trading volume of 572,234 shares, compared to its average volume of 1,388,799. The company has a fifty day moving average of $4.00 and a two-hundred day moving average of $4.32. The stock has a market capitalization of $965.71 million, a P/E ratio of -3.03 and a beta of 2.05. Autolus Therapeutics plc has a 12 month low of $2.01 and a 12 month high of $7.45. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). Equities research analysts forecast that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.